Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Bank of America

Bank of America initiated coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a research note issued to investors on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating and a $75.00 price objective on the stock.

Several other research analysts have also commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Needham & Company LLC upped their price target on Definium Therapeutics from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Royal Bank Of Canada upped their price target on Definium Therapeutics from $57.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Piper Sandler restated an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Finally, Robert W. Baird lifted their price objective on shares of Definium Therapeutics from $57.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $63.00.

Definium Therapeutics Stock Performance

Shares of DFTX stock opened at $45.40 on Tuesday. The stock has a market capitalization of $6.10 billion, a price-to-earnings ratio of -13.24 and a beta of 2.23. Definium Therapeutics has a one year low of $8.70 and a one year high of $49.70. The company’s 50-day simple moving average is $41.62 and its 200-day simple moving average is $27.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities analysts anticipate that Definium Therapeutics will post -3.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Robert Barrow sold 29,208 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. This represents a 2.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the sale, the insider owned 174,633 shares in the company, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Wellington Management Group LLP bought a new stake in shares of Definium Therapeutics during the 2nd quarter worth about $138,755,000. Commodore Capital LP boosted its holdings in shares of Definium Therapeutics by 10.5% in the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after acquiring an additional 475,000 shares in the last quarter. Orbimed Advisors LLC bought a new position in shares of Definium Therapeutics in the third quarter valued at approximately $4,337,000. Two Sigma Investments LP increased its stake in shares of Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock valued at $3,495,000 after acquiring an additional 239,965 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Definium Therapeutics by 11.0% during the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after acquiring an additional 198,878 shares during the period. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.